This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter revenue up 9.2% year on year, loss after tax Rs 297m
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.2 pts less than Nifty Microcap 250 and 19.3 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended September 30, 2026, revenue from operations rose 9.2% to Rs 4,914.65 million from Rs 4,502.65 million, but profit after tax was a loss of Rs 297.00 million versus Rs 336.22 million. Exceptional costs of Rs 19.26 million arose from the Vinpai open offer. The board also approved a rights issue of up to Rs 250 crore and noted an SEBI administrative warning over disclosure violations.
Revenue growth and lower loss help, but weak margins may pressure the stock. The rights issue can fund growth but dilute holders.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹491.5 Cr | ₹459.8 Cr | +6.9% |
| Operating profit | −₹38.28 Cr | −₹4.32 Cr | loss widened |
| Profit after tax | −₹29.70 Cr | −₹14.95 Cr | loss widened |
| EBITDA margin | 0.1% | 7.3% | −7.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.